Dialpad Introduces TruCaaS to Business Communications With Launch of Dialpad Meetings for Single, Unified View
13.7.2021 13:10:00 EEST | Business Wire | Press release
Dialpad Inc., the industry leader in AI-powered communication and collaboration, today announced a truly unified approach to communications as a service. With the launch of Dialpad Meetings, the company is bringing its suite of products closer together across both business communications and customer engagement all on one unified, aesthetically cohesive platform with AI at its core.
Dialpad Meetings, formerly known as UberConference, adds new capabilities and establishes the Dialpad cloud communications platform as the one place for a truly unified Communications as a Service (TruCaaS) experience. With a TruCaaS solution delivered through a single pane of glass with an intuitive interface, Dialpad helps customers simplify business collaboration and avoid the growing phenomenon of “app overload.”
“At Dialpad, we believe when the right people come together anything is possible, and we want our brand to reflect this spirit of connection, collaboration and productivity in this new work-from-anywhere world,” said Craig Walker, CEO of Dialpad. “With today’s announcements, we are resetting expectations for communication experiences by building a business communication platform that is more beautiful, accessible, easy to deploy and easy to use — to help businesses of any size start, grow and scale.”
To bring the vision of TruCaaS to life, Dialpad is making the following capabilities available in its single, powerful platform:
-
Dialpad Meetings - The reliable UberConference technology customers know and love with a new look and set of features, including:
- Video conferencing in HD quality for an in-the-room experience
- Real-time Voice Intelligence (Vi™) provides live note-taking and automated transcription analysis, enabling attendees to focus on the conversation and ensure key moments are not missed.
- Start and join Dialpad Meetings from any direct message, group message or channel within the Dialpad app. With Dialpad Meetings natively built into the platform, users are not required to manage multiple tabs or windows.
- Emoji reactions and expressions build social connections with team members and provide feedback in real-time without interruptions.
- Dialpad Channels - With one click, Dialpad Channels offers teams a “light lift” collaboration tool for quick text and/or audio conversations. By providing a space for informal chats, office hours and other water cooler conversations, Dialpad Channels combats video conferencing fatigue and reduces the need for formal 30-minute meetings.
- Mobile screen sharing - Dialpad users can now share their screens on phone calls, whether everyone is a Dialpad user or not. No need to set an official meeting or jump onto a conference call to quickly resolve issues, collaborate on projects or do virtual walkthroughs.
- Global availability - Dialpad Meetings is available through the Dialpad platform with connectivity in 49 countries.
After winning TechCrunch Disrupt NYC in 2012 for UberConference and igniting the work-from-anywhere movement, Dialpad is disrupting an industry built on legacy thinking. As part of this vision and aligned with its TruCaaS approach, Dialpad is launching its Work Beautifully campaign to further support and enable the hybrid workplace.
“Work Beautifully is the big-picture concept that the Dialpad brand and products aspire to. Not only do our talk, messaging, meetings and contact center products work beautifully, they enable others to work beautifully and collaboratively together,” said Morgan Norman, Chief Marketing Officer, Dialpad. “This bold, new visual identity honors Dialpad’s ground-breaking story, its history of innovation in communications, and is deeply rooted in the company’s core values: do the right thing, every voice matters, and experience first.”
The future of work is not restrained by employee or customer location, but is instead borderless; enabled by AI across every experience and seamlessly integrated into how people collaborate and create. Companies that embrace work-from-anywhere technology and empower employee and customer experiences with AI have a significant advantage over those that hold tight to outdated modes of communication, collaboration and productivity. Dialpad’s new release with integrated talk, messaging, meetings and contact center — all powered by AI across every experience — arrives at the right moment to help businesses thrive in this post-pandemic, work-from-anywhere world.
“Work Beautifully means simplicity and ease. Dialpad even takes notes and transcribes calls for us. It’s that flow state where work doesn’t feel like work anymore,” said Chad Pierce, Head of Building Technology, WeWork. “Dialpad makes it easy for our teams to stay close, wherever work finds them and frees our teams to collaborate from anywhere on the planet.”
Additional Resources
- Get started with Dialpad today on a 14-day free trial
- Learn more about Dialpad Channels
- Explore the what, how and why of Voice Intelligence in the contact center
- Discover how Dialpad utilizes AI to unify UCaaS and CCaaS
Social Networks:
- Web: https://www.dialpad.com/
- Blog: https://www.dialpad.com/blog/
- Twitter: https://twitter.com/dialpadHQ/
- LinkedIn: https://www.linkedin.com/company/dialpad/
- Facebook: https://www.facebook.com/Dialpadhq/
- Instagram: https://www.instagram.com/Dialpad/
About Dialpad
Dialpad is the leading cloud communications platform for talk, messaging, meetings and contact center in one beautiful app. Dialpad’s platform delivers AI across every employee and customer experience through real-time transcriptions, live agent coaching and sentiment analysis. More than 73,000 of the world’s most innovative businesses, including Domo, Motorola Solutions, Netflix, Splunk, Stripe, T-Mobile, Twitter, Uber and WeWork use Dialpad to connect and collaborate. Dialpad is backed by the world’s leading investors including Amasia, Andreessen Horowitz, Felicis Ventures, GV, ICONIQ Capital, OMERS Growth Equity, Salesforce Ventures, Scale Ventures, Section 32, SoftBank Corp., T-Mobile Ventures and Work-Bench. Visit www.dialpad.com for more information and to request a demo.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210713005389/en/
Contact information
Gavin Gustafson
gavin@dialpad.com
801-255-9915
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
